Evidence map›Paper›PMID 41596251›Full record

ReviewInternational journal of molecular sciences2026

The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.

Hangfei Jiang, Yueyin Chen, Xi Zeng, Rui Yang, Feng Zhang, Huanling Zhang, Erxiang Zhang, Xuzhang Wu, Deye Yan, Chunping Yu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hangfei JiangDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510230, China.
Yueyin ChenThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Xi ZengThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Rui YangThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Feng ZhangDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510230, China.
Huanling ZhangThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Erxiang ZhangThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Xuzhang WuThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Deye YanThe Third Clinical College, Guangzhou Medical University, Guangzhou 510230, China.
Chunping YuDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510230, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder urothelial carcinoma (BUC) ranks among the most common malignant tumors of the urinary system, with alarmingly high incidence and mortality rates. Current clinical treatments face challenges such as strong chemotherapy resistance and limited response rates to immunotherapy, creating an urgent need for novel alternative therapies. Natural products, characterized by multi-targeted antitumor activity, low toxicity, and broad availability, have emerged as highly promising adjunctive or alternative strategies in cancer treatment. Extensive research has elucidated the antitumor activities of natural products, including inhibition of cancer cell proliferation, induction of apoptosis, and modulation of the immune microenvironment. What's more, their bioactive components, such as terpenoids and polyphenols, can synergistically enhance therapeutic efficacy while reducing toxicity risks associated with traditional therapies. This review will examine the roles of terpenoids, phenolics, alkaloids, and other natural products in BUC treatment, to provide directions for future research.

Indexed as

Antineoplastic AgentsBiological ProductsUrinary Bladder NeoplasmsAnimalsApoptosisCell ProliferationDrug Resistance, NeoplasmHumansTerpenesAntineoplastic AgentsBiological ProductsTerpenesapoptosisbladder urothelial carcinomacell cycledrug resistanceinvasionnatural products

Identifiers

PMID41596251
PMCPMC12840891

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.